Loading
PTK7 is a cell-surface protein being studied as an address for cancer-directed treatments.
AACR 2024 abstract 2616 describes PTK7 and TROP2 as the two antigens bound by BCG033. The cited antibody-drug conjugate evidence is from cell and xenograft models; it does not establish clinical benefit or a companion diagnostic.
In plain words · PTK7 is a cell-surface protein being studied as an address for cancer-directed treatments.
PTK7 is a cell-surface protein being studied as an address for cancer-directed treatments.
Cell-surface antigen studied for binding and internalization of antibody-drug conjugates; the cited BCG033 abstract describes co-targeting with TROP2.
1 product aims at PTK7: antibody-drug conjugates. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Cell-surface antigen studied for binding and internalization of antibody-drug conjugates; the cited BCG033 abstract describes co-targeting with TROP2.
BCG033 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.
Query for this target: (TITLE:"PTK7" OR ABSTRACT:"PTK7") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PTK7, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/